Chronic kidney disease (CKD) could be added to the list of criteria for defining people at highest risk for future coronary events, Canadian researchers found. In a large cohort study, patients with only CKD had a significantly higher rate of myocardial infarction (MI) than those who only had diabetes (5.4 versus 6.9 per 1,000 person-years, P<0.0001), according to Marcello Tonelli, MD, of the University of Alberta, and colleagues.
Las enfermedades cardiovasculares (ECV) son la primera causa de muerte en nuestro país, siendo responsables del 31,8% de los fallecimientos. Sin embargo, en las mujeres esta proporción aumenta al 35,18%. Tras las ECV, se encuentran como principales causas de mortalidad femenina los tumores (22,35%) y las enfermedades del sistema respiratorio (9,14%)
Se dice que el uno es el número más solitario, pero también podría ser el más letal. Dos estudios recientes sugieren que vivir solo o sentir soledad pueden aumentar el riesgo de morir de enfermedad cardiaca o de cualquier causa de una persona. En un estudio, las personas con enfermedad cardiaca que vivían solas eran más propensas a morir que sus contrapartes que no vivían solas. Un segundo estudio mostró que las personas a partir de los 60 años de edad estaban en mayor riesgo de declive funcional y/o muerte si se sentían ignoradas, aisladas o reportaban una falta de compañía. Ambos estudios aparecen en la edición en línea del 18 de junio de la revista Archives of Internal Medicine.
Heart transplant patients are notorious for developing an aggressive form of coronary artery disease that can often result in heart failure, death or the need for repeat transplantation. The condition can also have a negative impact on future cardiac procedures, such as stenting.
The use of a cerebral embolic protection device during transcatheter aortic valve implantation (TAVI) system is feasible and safe, according to a study published in EuroIntervention.
Estudian una nueva técnica quirúrgica que disminuye el riesgo de fibrilación auricular tras la cirugía coronaria. La investigación ha sido presentada como comunicación y opta a premio en el XXI Congreso de la Sociedad Española de Cirugía Torácica-Cardiovascular (SECTCV).
Stentys has announced that it has enrolled the first patient in its APPOSITION IV clinical study using its new Self-Apposing Sirolimus-eluting stent. The randomised study will enrol 150 heart attack patients who will be treated with either the Stentys stent or Medtronic s Resolute drug-eluting stent, and will compare stent apposition in both groups at four and nine months after treatment.
Nearly 50% of patients suffering from a diseased mitral heart valve with severe, symptomatic regurgitation are denied open-heart surgery because it is considered too risky; in the future, Transcatheter Mitral Valve Implantation (TMVI) may offer new hope for these patients.
Svelte® Medical Systems today announced the start of the FAASTER (First Assessment of the Acrobat Stenting Technique European Post-Market Registry) study in clinical sites across Europe. FAASTER is a real world, multi-center registry assessing the procedural success and resource utilization associated with the Svelte coronary stent mounted on an Integrated Delivery System (IDS) in relation to target lesion and vessel complexity (as defined by NAVI-score) and selected catheter approach (diagnostic or guiding). Up to 1,500 patients will be evaluated in the study.
STENTYS S.A. (STNT.PA),a medical technology company commercializing the world s first and only Self-Apposing® Stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the first patient in its APPOSITION IV clinical study using its new Self-Apposing® Sirolimus-eluting stent. The randomized study will enroll 150 heart attack patients who will be treated with either the STENTYS stent or Medtronic s Resolute® drug-eluting stent, and will compare stent apposition in both groups at four and nine months after treatment.
An FDA advisory panel has voted 11-0, with one abstention, to recommend expanding the indication for the Sapien Transcatheter Heart Valve to include high-risk patients with severe aortic stenosis. The FDAs Circulatory Systems Advisory Committee agreed Wednesday that Edwards Lifesciences Sapien valve is safe and effective for patients who are candidates for aortic valve replacement but who have an open-heart surgery mortality risk of 15% or more. The Sapien was approved in 2011 for inoperable patients, but Edwards is seeking the broader "high-risk" indication, which would allow the device to be a treatment option for a greater number of patients.
Cardiosolutions Inc., an emerging leader in structural heart solutions for valvular heart disease, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Dexterity™ Steerable Introducer, a next generation structural heart access introducer and delivery conduit. The Dexterity™ Steerable Introducer is designed to provide physicians straightforward and uncomplicated access to the heart anatomy by simplifying the cardiac trans-septal procedure and facilitating passage of therapies into the entire left atrium, left ventricle and associated heart structures. The Dexterity™ Steerable Introducer is intended to be used for the advancement and delivery of various cardiovascular catheters into the heart, including the left side of the cardiac anatomy through the inter-atrial septum.
El experto de la Sociedad Española de Arteriosclerosis, Luis Masana, aseguró durante su participación en el 80 Congreso de la Sociedad Europea de Arteriosclerosis (EAS) que existen nuevos abordajes terapéuticos que permitirán descensos adicionales de LDL de hasta un 70%.
Presentations at EuroPCR 2012 Enjoy Spirited Debate; Implications for Clinical Practice of Interventional Cardiologists
Development of more biocompatible polymers, as well as thinner stent struts and polymer coatings, is improving efficacy and safety of second-generation drug-eluting stents (DES). Given the link between certain polymers and chronic inflammatory responses to DES, it is a natural next step to develop either a third-generation bioresorbable polymer on a durable platform or a fourth-generation bioresorbable polymer on a bioresorbable platform.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos